BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal

BioSpace

Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb.

pharminent May 12, 2026 (Last updated: May 12, 2026)

BioSpace

Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb.

Related Stories